3 Canadian Healthcare Stocks With Revenue Growth Over 7%
Published . Updated .
This report is about Health.
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
A fund of health-care companies
- XBI SPDR S&P Biotech
A fund of biotechnology companies
- UNH UnitedHealth+10.8%
A large health insurer
- JNJ Johnson & Johnson+0.5%
A large health-care company
- LLY Eli Lilly+14.8%
A large drug maker
- PFE Pfizer+9.7%
A large drug maker
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -2.01% | -0.19% | base | after close | after close | after close | after close |
| XBI | -1.12% | +2.16% | base | after close | after close | after close | after close |
| UNH | -2.66% | -0.29% | base | after close | after close | after close | after close |
| JNJ | -3.73% | -2.35% | base | after close | after close | after close | after close |
| LLY | -2.64% | -0.26% | base | after close | after close | after close | after close |
| PFE | -1.93% | -0.50% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
3 Canadian Healthcare Stocks With Revenue Growth Over 7% Yahoo Finance Singapore
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| JNJ | three days earlier | -2.35% | final price |
| JNJ | five days earlier | -3.73% | final price |
| LLY | three days earlier | -0.26% | final price |
| LLY | five days earlier | -2.64% | final price |
| PFE | three days earlier | -0.50% | final price |
| PFE | five days earlier | -1.93% | final price |
| UNH | three days earlier | -0.29% | final price |
| UNH | five days earlier | -2.66% | final price |
| XBI | three days earlier | +2.16% | final price |
| XBI | five days earlier | -1.12% | final price |
| XLV | three days earlier | -0.19% | final price |
| XLV | five days earlier | -2.01% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Maria Elvira Salazar sold Unitedhealth Group (UNH), worth $1,001 - $15,000 on 24 Sep 2026. That is 30 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Unitedhealth Group (UNH) (jointly held), worth $15,001 - $50,000 on 23 Sep 2026. That is 31 days before publication. Filed 13 Oct 2026. View the filing.
- Rep. Kevin Hern sold Unitedhealth Group (UNH) (jointly held), worth $15,001 - $50,000 on 10 Sep 2026. That is 44 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 29 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 46 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 31 Jul 2026. That is 85 days before publication. Filed 22 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “3 Canadian Healthcare Stocks With Revenue Growth Over 7%” looks
25 out of 100
“3 Canadian Healthcare Stocks With Revenue Growth Over 7%” scores 25 out of 100. The score uses 2 sources.